CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 Chen, 2014, Non-small-cell lung cancers: a heterogeneous set of diseases, Nat Rev Cancer, 14, 535, 10.1038/nrc3775 Blanco-Prieto, 2017, Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units, Sci Rep, 7, 41151, 10.1038/srep41151 Davidson, 2013, The pivotal role of pathology in the management of lung cancer, J Thorac Dis, 5, S463 Ettinger, 2013, Non-small cell lung cancer, version 2.2013, J Natl Compr Canc Netw, 11, 645, 10.6004/jnccn.2013.0084 Assi, 2018, Immune checkpoint inhibitors in advanced non-small cell lung cancer, Cancer, 124, 248, 10.1002/cncr.31105 Bergsma, 2017, Radiotherapy for Oligometastatic Lung Cancer, Front Oncol, 7, 210, 10.3389/fonc.2017.00210 Rolfo, 2017, Immunotherapy in NSCLC: A Promising and Revolutionary Weapon, Adv Exp Med Biol, 995, 97, 10.1007/978-3-319-53156-4_5 Elliott, 2017, Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity, Front Immunol, 8, 86, 10.3389/fimmu.2017.00086 Aerts, 2013, Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer, Cancer Res, 73, 2381, 10.1158/0008-5472.CAN-12-3932 Allavena, 2012, Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment, Clin Exp Immunol, 167, 195, 10.1111/j.1365-2249.2011.04515.x Chanmee, 2014, Tumor-associated macrophages as major players in the tumor microenvironment, Cancers, 6, 1670, 10.3390/cancers6031670 Lewis, 2006, Distinct role of macrophages in different tumor microenvironments, Cancer Res, 66, 605, 10.1158/0008-5472.CAN-05-4005 Mantovani, 2017, Tumour-associated macrophages as treatment targets in oncology, Nat Rev Clin Oncol, 14, 399, 10.1038/nrclinonc.2016.217 Lewis, 2007, Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2, Cancer Res, 67, 8429, 10.1158/0008-5472.CAN-07-1684 Ugel, 2015, Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages, J Clin Invest, 125, 3365, 10.1172/JCI80006 Geissmann, 2010, Development of monocytes, macrophages, and dendritic cells, Science, 327, 656, 10.1126/science.1178331 Van Overmeire, 2016, M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment, Cancer Res, 76, 35, 10.1158/0008-5472.CAN-15-0869 Bingle, 2002, The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, J Pathol, 196, 254, 10.1002/path.1027 Forget, 2014, Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer, PLoS One, 9, 10.1371/journal.pone.0098623 De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 Murdoch, 2007, Expression of Tie-2 by human monocytes and their responses to angiopoietin-2, J Immunol, 178, 7405, 10.4049/jimmunol.178.11.7405 Achkova, 2016, Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer, Biochem Soc Trans, 44, 333, 10.1042/BST20150245 Coelho, 2015, Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers, Future Oncol, 11, 3233, 10.2217/fon.15.207 Stanley, 1997, Biology and action of colony--stimulating factor-1, Mol Reprod Dev, 46, 4, 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V Dwyer, 2017, Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling, Cancers, 9, 68, 10.3390/cancers9060068 De Palma, 2013, Macrophage regulation of tumor responses to anticancer therapies, Cancer Cell, 23, 277, 10.1016/j.ccr.2013.02.013 Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014 Ruffell, 2012, Differential macrophage programming in the tumor microenvironment, Trends Immunol, 33, 119, 10.1016/j.it.2011.12.001 Kubota, 2009, M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis, J Exp Med, 206, 1089, 10.1084/jem.20081605 Kaminska, 2006, Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor, Oncology, 70, 115, 10.1159/000093002 Katsumata, 1996, Serum levels of cytokines in patients with untreated primary lung cancer, Clin Cancer Res, 2, 553 Priceman, 2010, Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy, Blood, 115, 1461, 10.1182/blood-2009-08-237412 Woodard, 2016, Lung Cancer Staging and Prognosis, Cancer Treat Res, 170, 47, 10.1007/978-3-319-40389-2_3 Bach, 2012, Benefits and harms of CT screening for lung cancer: a systematic review, JAMA, 307, 2418, 10.1001/jama.2012.5521 Gyoba, 2016, Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood, Plasma, Serum and Sputum: A Review and Summary of Current Literature, Int J Mol Sci, 17, 494, 10.3390/ijms17040494